Day: March 1, 2021

VANCOUVER, British Columbia, March 01, 2021 (GLOBE NEWSWIRE) — Orezone Gold Corporation (TSX.V: ORE OTCQX: ORZCF) is pleased to announce it has entered into a binding letter of intent for a silver streaming agreement with EURO Ressources S.A. (“EURO”) to sell 50% of the future payable silver production from the Bomboré Gold Project for an upfront cash payment of US$7,150,000.HighlightsRealizes value for silver not included in the 2019 feasibility study – The value of the silver is not included in the 2019 Bomboré feasibility study due to a lack of assay data. This streaming deal now unlocks that value while allowing the Company to participate in the remaining 50% silver values;Provides immediate cash for exploration at Bomboré – The upfront sale of the silver stream will allow the Company to conduct exploration drilling on near-term...

NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the formation of an independent Scientific Advisory Board comprising leaders in the fields of immunotherapy, lung and skin cancers. The Scientific Advisory Board will work closely with Checkpoint leadership to further develop Checkpoint’s novel treatments for patients with solid tumor cancers, including cosibelimab and CK-101.“We are honored to have the opportunity to work with such a distinguished group of clinical and scientific leaders on the development of our pipeline products, including cosibelimab in our initial indications in skin and lung cancers, and CK-101 in lung cancer, as well as helping us identify new opportunities for development,”...

Collaboration will Leverage Access to the NURTuRE Patient Biobank and Evotec’s PanHunter Multi-Omics Platform to Characterize Molecular Drivers, Identify and Validate Novel Targets and Drive Patient Stratification Strategies in Kidney DiseaseCollaboration Will Focus on Polycystic Kidney Disease (PKD), Lupus Nephritis, IgA Nephropathy and Other Primary Glomerular DiseasesVANCOUVER, British Columbia and SEATTLE, March 01, 2021 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (NASDAQ: KDNY) and Evotec SE today announced a strategic collaboration focused on the discovery and development of novel precision medicine therapies for patients with chronic kidney diseases. Based on Evotec’s proprietary comprehensive molecular datasets from thousands of patients across chronic kidney diseases of multiple underlying etiologies, Chinook and Evotec...

PHILADELPHIA, March 01, 2021 (GLOBE NEWSWIRE) — Hill International (NYSE:HIL), the global leader in managing construction risk, announced today that it will release its financial results for the fourth quarter and full year ending on December 31, 2020 on Tuesday, March 16, 2021, after the close of the stock market. Raouf Ghali, Hill’s Chief Executive Officer, and Todd Weintraub, Senior Vice President and Chief Financial Officer, will host a conference call on Wednesday, March 17, 2021, at 9:00 am Eastern Standard Time to discuss the results.Interested parties may participate in the call by dialing (877) 407-9753 (Domestic) or (201) 493-6739 (International) approximately 10 minutes before the call is scheduled to begin and asking to be connected to the Hill International Conference Call. To listen to the live call online, please...

NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) — Better Choice Company (OTCQX: BTTR) (“Better Choice”), an animal health and wellness company, today announced Chief Executive Officer, Scott Lerner and Executive Vice President of Strategy, Rob Sauermann, will be speaking at the D.A. Davidson 4th Annual Consumer Growth Conference on Thursday, March 11th at 11:00 a.m. ET.Scott Lerner, CEO of Better Choice, stated, “We are pleased to have been invited by D.A. Davidson to present our story at their Consumer Growth Conference. We are looking forward to outlining our exciting blueprint for success as we are quickly becoming a force in the fast-growing animal health and wellness sector.”The 4th Annual Consumer Growth Conference will feature company presentations, panel discussions, one-on-ones and small group meetings with company executives.About...

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES

Net profit attributable to the Company for the full year 2020 was $12.0 million, compared with $62.1 million in the previous year.Adjusted EBITDA including unconsolidated affiliates1 was $796.1 million in 2020, representing a 3.1% decrease compared with the previous year.Net cash provided by operating activities increased by 20.5% to $438.2 million compared to $363.6 million in 2019.Cash available for distribution (“CAFD”) was $200.7 million in 2020, 5.5% up on the previous year.2021 CAFD target guidance established in the range of $220 million to $240 million.Over $300 million in equity investments closed in 2020 and approximately $280 million new equity investments already agreed for 2021.Mid-term CAFD per share growth target set in the range of 5% to 8%2.Continued focused on ESG priorities, with strong ratings.March 1, 2021 – Atlantica...